Literature DB >> 16684822

Analysis of DAX1 (NR0B1) and steroidogenic factor-1 (NR5A1) in children and adults with primary adrenal failure: ten years' experience.

Lin Lin1, Wen-Xia Gu, Gokhan Ozisik, Wing S To, Catherine J Owen, J Larry Jameson, John C Achermann.   

Abstract

CONTEXT: Primary adrenal failure is a life-threatening condition that can be caused by a range of etiologies, including autoimmune, metabolic, and developmental disorders. The nuclear receptors DAX1 (NR0B1) and steroidogenic factor-1 (SF1/Ad4BP, NR5A1) play an important role in adrenal development and function, and mutations in these transcription factors have been found in patients with adrenal hypoplasia.
OBJECTIVE: Our objective was to investigate the prevalence of DAX1 and SF1 mutations in children and adults with primary adrenal failure of unknown etiology (i.e. not caused by congenital adrenal hyperplasia, adrenoleukodystrophy, or autoimmune disease). PATIENTS: One hundred seventeen patients were included. Eighty-eight individuals presented in infancy or childhood with adrenal hypoplasia or primary adrenal failure of unknown etiology (n = 64 46,XY phenotypic males; n = 17 46,XY gonadal dysgenesis/impaired androgenization; n = 7 46,XX females). Twenty-nine individuals presented in adulthood with Addison's disease of unknown etiology.
METHODS: Mutational analysis of DAX1 (NR0B1) (including exon 2alpha/1A) and SF1 (NR5A1) was done by direct sequencing.
RESULTS: DAX1 mutations were found in 58% (37 of 64) of 46,XY phenotypic boys referred with adrenal hypoplasia and in all boys (eight of eight) with hypogonadotropic hypogonadism and a family history suggestive of adrenal failure in males. SF1 mutations causing adrenal failure were found in only two patients with 46,XY gonadal dysgenesis. No DAX1 or SF1 mutations were identified in the adult-onset group.
CONCLUSIONS: DAX1 mutations are a relatively frequent cause of adrenal failure in this group of boys. SF1 mutations causing adrenal failure in humans are rare and are more likely to be associated with significant underandrogenization and gonadal dysfunction in 46,XY individuals.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16684822      PMCID: PMC1865080          DOI: 10.1210/jc.2006-0603

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  48 in total

1.  Adrenal hypoplasia congenita with hypogonadotropic hypogonadism: evidence that DAX-1 mutations lead to combined hypothalmic and pituitary defects in gonadotropin production.

Authors:  R L Habiby; P Boepple; L Nachtigall; P M Sluss; W F Crowley; J L Jameson
Journal:  J Clin Invest       Date:  1996-08-15       Impact factor: 14.808

Review 2.  Mutations in NR0B1 (DAX1) and NR5A1 (SF1) responsible for adrenal hypoplasia congenita.

Authors:  J K Phelan; E R McCabe
Journal:  Hum Mutat       Date:  2001-12       Impact factor: 4.878

Review 3.  Familial occurrence of the IMAGe association: additional clinical variants and a proposed mode of inheritance.

Authors:  Ignacio Bergadá; Graciela Del Rey; Pablo Lapunzina; César Bergadá; Marc Fellous; Silvia Copelli
Journal:  J Clin Endocrinol Metab       Date:  2005-03-15       Impact factor: 5.958

4.  Blockage of the rete testis and efferent ductules by ectopic Sertoli and Leydig cells causes infertility in Dax1-deficient male mice.

Authors:  B Jeffs; J J Meeks; M Ito; F A Martinson; M M Matzuk; J L Jameson; L D Russell
Journal:  Endocrinology       Date:  2001-10       Impact factor: 4.736

5.  A novel mutation in DAX1 causes delayed-onset adrenal insufficiency and incomplete hypogonadotropic hypogonadism.

Authors:  A Tabarin; J C Achermann; D Recan; V Bex; X Bertagna; S Christin-Maitre; M Ito; J L Jameson; P Bouchard
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

6.  NR0B1A: an alternatively spliced form of NR0B1.

Authors:  John Ho; Yao-Hua Zhang; Bing-Ling Huang; Edward R B McCabe
Journal:  Mol Genet Metab       Date:  2004-12       Impact factor: 4.797

Review 7.  Testicular dysgenesis without adrenal insufficiency in a 46,XY patient with a heterozygous inactive mutation of steroidogenic factor-1.

Authors:  Tomonobu Hasegawa; Maki Fukami; Naoko Sato; Noriyuki Katsumata; Goro Sasaki; Keiko Fukutani; Ken-Ichirou Morohashi; Tsutomu Ogata
Journal:  J Clin Endocrinol Metab       Date:  2004-12       Impact factor: 5.958

8.  Role of Ahch in gonadal development and gametogenesis.

Authors:  R N Yu; M Ito; T L Saunders; S A Camper; J L Jameson
Journal:  Nat Genet       Date:  1998-12       Impact factor: 38.330

9.  Gonadal dysgenesis without adrenal insufficiency in a 46, XY patient heterozygous for the nonsense C16X mutation: a case of SF1 haploinsufficiency.

Authors:  Delphine Mallet; Patricia Bretones; Laurence Michel-Calemard; Frederique Dijoud; Michel David; Yves Morel
Journal:  J Clin Endocrinol Metab       Date:  2004-10       Impact factor: 5.958

10.  An alternate translation initiation site circumvents an amino-terminal DAX1 nonsense mutation leading to a mild form of X-linked adrenal hypoplasia congenita.

Authors:  Gokhan Ozisik; Giovanna Mantovani; John C Achermann; Luca Persani; Anna Spada; Jeffrey Weiss; Paolo Beck-Peccoz; J Larry Jameson
Journal:  J Clin Endocrinol Metab       Date:  2003-01       Impact factor: 5.958

View more
  59 in total

1.  Two novel DAX1 gene mutations in Chinese patients with X-linked adrenal hypoplasia congenita: clinical, hormonal and genetic analysis.

Authors:  C M Wu; H B Zhang; Q Zhou; L Wan; J Jin; L Ni; Y J Pan; X Y Wu; L Y Ruan
Journal:  J Endocrinol Invest       Date:  2011-01-26       Impact factor: 4.256

Review 2.  Adrenocortical stem and progenitor cells: implications for adrenocortical carcinoma.

Authors:  Derek P Simon; Gary D Hammer
Journal:  Mol Cell Endocrinol       Date:  2012-01-13       Impact factor: 4.102

3.  Heterozygous missense mutations in steroidogenic factor 1 (SF1/Ad4BP, NR5A1) are associated with 46,XY disorders of sex development with normal adrenal function.

Authors:  Lin Lin; Pascal Philibert; Bruno Ferraz-de-Souza; Daniel Kelberman; Tessa Homfray; Assunta Albanese; Veruska Molini; Neil J Sebire; Silvia Einaudi; Gerard S Conway; Ieuan A Hughes; J Larry Jameson; Charles Sultan; Mehul T Dattani; John C Achermann
Journal:  J Clin Endocrinol Metab       Date:  2007-01-02       Impact factor: 5.958

Review 4.  Adrenocortical stem and progenitor cells: unifying model of two proposed origins.

Authors:  Michelle A Wood; Gary D Hammer
Journal:  Mol Cell Endocrinol       Date:  2010-11-20       Impact factor: 4.102

Review 5.  Hypogonadotropic hypogonadism in subjects with DAX1 mutations.

Authors:  Unmesh Jadhav; Rebecca M Harris; J Larry Jameson
Journal:  Mol Cell Endocrinol       Date:  2011-06-13       Impact factor: 4.102

6.  X-linked adrenal hypoplasia congenita: a novel DAX1 missense mutation and challenges for clinical diagnosis in Africa.

Authors:  Aimé Lumaka; Gerrye Mubungu; Celestin Nsibu; Bruno-Paul Tady; Tshilobo Lukusa; Koenraad Devriendt
Journal:  Eur J Pediatr       Date:  2011-07-08       Impact factor: 3.183

7.  Evidence of adrenal failure in aging Dax1-deficient mice.

Authors:  Joshua O Scheys; Joanne H Heaton; Gary D Hammer
Journal:  Endocrinology       Date:  2011-07-05       Impact factor: 4.736

Review 8.  The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders.

Authors:  Walter L Miller; Richard J Auchus
Journal:  Endocr Rev       Date:  2010-11-04       Impact factor: 19.871

9.  A non-surgical approach to 46,XY differences in sex development through hormonal suppression at puberty: a single-center case series study.

Authors:  Katie L Canalichio; Margarett Shnorhavorian; Anne-Marie Amies Oelschlager; Linda Ramsdell; Christina Fisher; Margaret P Adam; Patricia Y Fechner
Journal:  Endocrine       Date:  2020-07-08       Impact factor: 3.633

Review 10.  Steroidogenic factor-1 (SF-1, Ad4BP, NR5A1) and disorders of testis development.

Authors:  L Lin; J C Achermann
Journal:  Sex Dev       Date:  2008-11-05       Impact factor: 1.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.